AMENDMENTS

In the Claims

Claims 1-80 (canceled).

81. (Currently amended) The composition of claim ~~80~~ 159, wherein the CoQ_n of formula II, wherein n is 1 to 10.

82. (Currently amended) The composition of claim ~~80~~ 159, wherein the CoQ_n of formula II, wherein n is 6 to 10.

83. (Previously presented) The composition of claim 82, wherein the CoQ_n of formula II, wherein n is 10.

84. (Previously presented) The composition of claim 83, comprising about 0.1 to about 40% w/w ~~active agent~~ ubiquinone or DHEA.

85. (Previously presented) The composition of claim 84, comprising about 1 to about 20% w/w ~~active agent~~ ubiquinone or DHEA.

86. (Previously presented) The composition of claim 159, wherein the compound of formula (I) is dehydroepiandrosterone, wherein R and R' are each hydrogen and the broken line represents a double bond.

87. (Previously presented) The composition of claim 159, wherein the compound of formula (I) is 16-alpha bromoepiandrosterone, wherein R is Br, R^1 is H, and the broken line represents a double bond.

88. (Previously presented) The composition of claim 159, wherein the compound of formula (I) is 16-alpha-fluoro epiandrosterone, wherein R is F, R^1 is H and the broken line represents a double bond.

89. (Previously presented) The composition of claim 159, wherein the compound of formula (I) is etiocholanolone, wherein R and R^1 are each hydrogen and the broken line represents a double bond.

90. (Previously presented) The composition of claim 159, wherein the compound of formula (I) is dehydroepiandrosterone sulfate, wherein R is H, R^1 is SO_2OM and M is a sulfatide group as defined above, and the broken line represents a single bond.

91. (Previously presented) The composition of claim 159, wherein in the compound of formula (1), R is halogen selected from Br, Cl or F, R^1 is H, and the broken line represents a double bond.

92. (Previously presented) The composition of claim 159, wherein the compound of formula (I) is 16-alpha-fluoro epiandrosterone.

93. (Previously presented) The composition of claim 159, wherein the compound of formula (I) is selected from dehydroepiandrosterone, 16-alpha-bromoepiandrosterone, 16-alpha-fluoro epiandrosterone, etiocholanolone, dehydroepiandrosterone sulfate or pharmaceutically or veterinarily acceptable salts thereof.

94. (Currently amended) The composition of claim ~~80~~ 159, wherein the carrier or diluent comprises a pharmaceutically or veternarily acceptable carrier or diluent.

95. (Previously presented) The composition of claim 94, wherein the carrier or diluent is selected from solid or liquid carriers or diluents, and the active agent comprises liquid or solid particles.

96. (Currently amended) The composition of claim 94, further comprising an agent selected from folinic acid, pharmaceutrically or veternarily acceptable salts of folinic acid, ~~other therapeutic agents,~~ preservatives, antioxidants, flavoring agents, volatile oils, buffering agents, dispersants or surfactants.

Claims 97-114 (canceled).

115. (Currently amended) The inhalable or respirable formulation of claim ~~114~~ 159, which is an aerosol or spray comprising liquid or solid particles ~~of the active agent , and which may further comprise an ingredient selected from folinic acid, other therapeutic agents, preservatives, antioxidants, flavoring agents, volatile agents, buffering agents, dispersants or surfactants~~.

116. (Currently amended) The formulation of claim 115, comprising an inhalable or respirable formulation comprising powdered or liquid particles of the ~~active agent~~ formulation about 0.05 μm to about 10 μm in size.

117. (Currently amended) The formulation of claim 116, comprising an inhalable or respirable aerosol formulation comprising powdered or liquid particles of the ~~active agent~~ formulation about 0.1 μm to about 5 μm in size.

118. (Currently amended) The formulation of claim 115, which comprises a ~~nasal or~~ intrapulmonary aerosol formulation comprising powdered or liquid particles of the ~~active agent~~ formulation about 10 μm to about 100 μm in size.

119. (Currently amended) The formulation of claim 118, which comprises powdered or liquid particles of the ~~active agent~~ formulation about 10 μm to about 50 μm in size.

120. (Previously presented) The formulation of claim 95, wherein the carrier comprises a hydrophobic carrier.

121. (Previously presented) A kit comprising the formulation of claim 94, and a delivery device.

122. (Previously presented) The kit of claim 121, wherein the delivery device delivers individual pre-metered doses of the formulation.

123. (Previously presented) The kit of claim 121, wherein the delivery device comprises an inhaler.

124. (Previously presented) The kit of claim 121, wherein the inhaler comprises a

nebulizer or insufflator.

125. (Previously presented) The kit of claim 121, wherein the delivery device comprises a compression inhaler, and the formulation comprises a suspension or solution in an aqueous or non-aqueous liquid or an oil-in-water or water-in-oil emulsion.

126. (Previously presented) The kit of claim 121, wherein the formulation is provided in a pierceable or openable capsule or cartridge.

127. (Previously presented) The kit of claim 121, wherein the formulation is provided in a pierceable or openable capsule or cartridge.

Claims 128-158 (canceled).

159. (Currently amended) ~~The pharmaceutical composition of claim 80, further comprising~~ A pharmaceutical composition, comprising a ubiquinone, or pharmaceutically or veterinarily acceptable salt thereof, wherein the ubiquinone has the chemical formula



(CoQn) (II)

;

wherein n=1 to 12, and a dehydroepiandrosterone (DHEA), a pharmaceutically or veterinarily acceptable salts thereof, or a mixture thereof, the dehydroepiandrosterone having the chemical formula



(I); (DHEA) (I)

wherein the broken line represents a single or a double bond; R is hydrogen or a halogen; the H at position 5 is present in the alpha or beta configuration or the compound of chemical formula I comprises a racemic mixture of both configurations; and R1 is hydrogen or SO_2OM, wherein M is selected from the group consisting of H, Na, sulfatide $-SO_2O-CH_2CHCH_2OCOR^3$; and phosphatide

$$\begin{array}{l} \\ | \\ OCOR^2 \end{array}$$

$$\begin{array}{l} O \\ || \\ -P-OCH_2CHCH_2OCOR^3 \\ || \quad\quad | \\ O \quad\quad OCOR^2 \end{array}$$

, wherein R^2 and R^3, which may be the same or different, are straight or branched (C_1-C_{14}) alkyl or glucuronide,



3,4-Dihydroxy-3,5,6-trimethyl-tetrahydro-pyran-2-carboxylic acid

; wherein the ubiquinone, or pharmaceutically or veterinarily acceptable salts thereof, and the DHEA, or pharmaceutically or veterinarily acceptable salts thereof, ~~is~~ are present in ~~an~~ amounts effective for altering levels of, or sensitivity to, adenosine in a subject's tissue (s), or treating bronchoconstriction, lung inflammation or allergy(ies), COPD or a disease associated with either of them ; wherein said pharmaceutical composition is an inhalable, respirable, or intrapulmonary formulation.